Outcomes and compliance with standards of care in ANCA-associated vasculitis: insights from a large multi-region audit

Pearce, Fiona, McGrath, Catherine, Sandhu, Ravinder, Packham, Jon C., Watts, Richard, Rhodes, Benjamim, Reem, Al-Jayyousi, Harper, Lorraine, Obrenovic, Karen and Lanyon, Peter C. (2018) Outcomes and compliance with standards of care in ANCA-associated vasculitis: insights from a large multi-region audit. Rheumatology Advances in Practice . ISSN 2514-1775

Full text not available from this repository.


Objectives: We aimed to conduct a large audit of routine care for patients with ANCA-associated vasculitis (AAV).

Methods: We invited all 34 hospitals within one health region in England to undertake a retrospective case note audit of all patients newly-diagnosed or treated with Cyclophosphamide or Rituximab for AAV April 2013-December 2014. We compared clinical practice to the BSR guideline for the management of adults with AAV, and use of Rituximab to the NHS England commissioning policy and NICE Technology Appraisal.

Results: We received data from 213 patients. Among 130 newly diagnosed patients, delay from admission to diagnosis ranged from 0-53 days (median 6, IQR 3-10.5) for those diagnosed as in-patients. BVAS score was recorded in 8% at diagnosis. Remission at 6 months was achieved in 83% of patients. 1-year survival was 91.5%. 130 patients received Cyclophosphamide for new-diagnosis or relapse. The correct dose of i.v. cyclophosphamide (within 100mg of the target dose calculated for age, weight and creatinine) was administered in 58%. 25% of patients had an infection requiring hospital admission during or within 6 months of completing their cyclophosphamide therapy. 76 patients received Rituximab for new-diagnosis or relapse. 97% patients met NHS England or NICE eligibility criteria. PJP prophylaxis (recommended in the summary of product characteristics) was given in only 65% of patients.

Conclusion: We identified opportunities to improve care, including compliance with safety standards for delivery of cyclophosphamide. Development of a national treatment protocol / checklist to reduce this heterogeneity in care should be considered as a priority.

Item Type: Article
RIS ID: https://nottingham-repository.worktribe.com/output/945296
Keywords: ANCA-associated vasculitis; Audit; Routine care; Cyclophosphamide; Survival
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Epidemiology and Public Health
Identification Number: https://doi.org/10.1093/rap/rky025
Depositing User: Claringburn, Tara
Date Deposited: 11 Jul 2018 07:45
Last Modified: 04 May 2020 19:45
URI: https://eprints.nottingham.ac.uk/id/eprint/52824

Actions (Archive Staff Only)

Edit View Edit View